【药物名称】Diaziquone, CI-904, NSC-182986, AZQ
化学结构式(Chemical Structure):
参考文献No.46977
标题:Aziridinyl quinone anti-transplanted tumor agents
作者:Driscoll, J.S.; et al. (US Department of Health & Human Services)
来源:US 4146622
合成路线图解说明:

The reaction of chloranil (I) with ethyl carbamate (II) by means of Na in dry benzene gives 2,5-dichloro-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone (III), which is then condensed with aziridine (IV) by means of triethylamine in THF.

参考文献No.67162
标题:AZQ
作者:Cabanillas, F.; Blancafort, P.; Serradell, M.N.; Casta馿r, J.
来源:Drugs Fut 1981,6(6),338
合成路线图解说明:

The reaction of chloranil (I) with ethyl carbamate (II) by means of Na in dry benzene gives 2,5-dichloro-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone (III), which is then condensed with aziridine (IV) by means of triethylamine in THF.

参考文献No.607169
标题:Potential central nervous system antitumor agents. Azirinylbenzoquinones. 1
作者:Kahn, A.H.; Driscoll, J.S.
来源:J Med Chem 1976,19(2),313-317
合成路线图解说明:

The reaction of chloranil (I) with ethyl carbamate (II) by means of Na in dry benzene gives 2,5-dichloro-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone (III), which is then condensed with aziridine (IV) by means of triethylamine in THF.

参考文献No.700869
标题:
作者:Zubrod, C.G.; Rall, D.P.
来源:Anu Rev Pharmacol 1962,2109
合成路线图解说明:

The reaction of chloranil (I) with ethyl carbamate (II) by means of Na in dry benzene gives 2,5-dichloro-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone (III), which is then condensed with aziridine (IV) by means of triethylamine in THF.

参考文献No.800216
标题:Structure-antitumor activity relationships among quinone derivatives
作者:Driscoll, J.S.; et al.
来源:Cancer Chemother Rep 1974,4(2),1
合成路线图解说明:

The reaction of chloranil (I) with ethyl carbamate (II) by means of Na in dry benzene gives 2,5-dichloro-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone (III), which is then condensed with aziridine (IV) by means of triethylamine in THF.

Drug Information Express,Drug R&D,Chemical Database,Patent Search.
Copyright © 2006-2024 Drug Future. All rights reserved.Contact Us